Sponsored content brought to you by
Lateral flow assays (LFAs) have become indispensable tools in diagnostics valued for their speed, versatility, and accessibility. As developers and end users push for higher sensitivity and quantitative readouts, many challenges emerge that trace back to the quality and integrity of assay reagents. Among these, the properties of antibodies and antigens remain the most influential determinants of assay performance and reliability.
Challenge 1: Sensitivity and antibody affinity
Assay sensitivity is determined largely by the strength and stability of the antibody–antigen interaction. Suboptimal affinity, structural instability, or denaturation during conjugation can weaken signal intensity and increase the limit of detection. Even minor differences in antibody properties like isotype or glycosylation can alter gold particle conjugation as well as migration along the test strip, resulting in inconsistent line development. Achieving reproducible sensitivity depends on selecting and screening antibodies and antigens specifically for lateral flow performance under dynamic flow conditions.
Challenge 2: Cross-reactivity and matrix interference
Specificity defines assay accuracy, yet cross-reactivity remains a leading cause of false positives and background noise. Non-specific binding may occur due to shared epitopes, hydrophobic interactions, or matrix components that modify antibody conformation. These effects are especially pronounced in complex sample types such as serum, saliva, and food extracts. Careful selection of antibody pairs that recognize distinct, non-overlapping epitopes, combined with validation under relevant sample conditions, is essential to maintain high analytical specificity without compromising sensitivity.
Challenge 3: Antibody pairing and antigen quality
Selecting compatible antibody pairs and high-quality antigens is one of the most technically demanding steps in assay development. Even high-affinity antibodies can perform poorly when epitope overlap prevents effective capture and detection. Similarly, recombinant or partially denatured antigens may not replicate native conformations, leading to variable or misleading assay results. Consistent assay performance requires antigen sources that preserve native structure and antibody pairs verified for cooperative binding and reproducibility across production lots.
Building reliable assays through quality reagents
Every component of a lateral flow assay contributes to its analytical profile, but the biological reagents form its foundation. High-quality antibodies and antigens reduce development time, minimize troubleshooting, and support reproducibility from research to large-scale manufacturing.
Arista Biologicals supports diagnostic developers with validated antibodies, antigens, and colloidal gold conjugates specifically optimized for use in lateral flow assays. Each reagent is carefully characterized, helping assay developers achieve the sensitivity, specificity, and reproducibility required for today’s high-performance point-of-care diagnostics. With more than three decades of experience serving the global diagnostics industry, Arista remains a trusted partner in advancing robust, reproducible, and high-quality lateral flow assays.
Let us craft a project plan that meets your unique needs. www.fortislife.com
